Matthew Cooperberg and Charles Ryan discuss active surveillance in the low risk and low volume disease setting. The topics they highlight include defining the appropriate patient for active surveillance in 2018 and reaching a global consensus, how much age factors into active surveillance, how biomarkers and imaging are driving research and decision making in the active surveillance setting and where lifestyle, diet, and exercise fits in.

Biographies:
Matthew R. Cooperberg, MD, MPH Associate Professor of Urology; Epidemiology & Biostatistics Helen Diller Family Chair in Urology. Matthew Cooperberg received his undergraduate training from Dartmouth College, where he earned a degree in English with high honors. He then enrolled in Yale University's MD, MPH program, concurrently earning an MPH with a concentration in Health Policy from the School of Epidemiology and Public Health, and an MD from the School of Medicine. He completed his General Surgery and Urology training at the University of California, San Francisco, and subsequently continued at UCSF to complete a fellowship in Urologic Oncology. In 2009, Dr. Cooperberg was recruited to join the faculty at UCSF and the San Francisco Veterans Affairs Medical Center. Specializing in urologic cancer care, he is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, located primarily at the Mission Bay campus.  He also maintains privileges at San Francisco General Hospital. In 2013, Cooperberg received the first Helen Diller Family Chair in Urology and a secondary appointment in the Department of Epidemiology and Biostatistics. In 2015 he won the American Urological Association Gold Cystoscope Award, given annually to one urologist for contributions to the field in the first 10 years of practice.

Charles J. Ryan, MD


Read More:

Genomic Screening Should Be Done

Complete EAU 2018 Coverage